Translational research: Rett syndrome and tuberous sclerosis complex

Current Opinion in Pediatrics

Volumn 23, Issue 6, 2011, Pages 633-639

  Khwaja, Omar S ^a   Sahin, Mustafa ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

insulin like growth factor 1; methyl CpG binding protein 2; mTOR; TSC1; TSC2

Indexed keywords

METHYL CPG BINDING PROTEIN 2; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C; TUBERIN;

AUTISM; CENTRAL NERVOUS SYSTEM; CHILD; COGNITION; EPILEPSY; HUMAN; MOLECULAR PATHOLOGY; NEUROPSYCHIATRY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; RETT SYNDROME; REVIEW; TRANSLATIONAL RESEARCH; TUBEROUS SCLEROSIS;

ANIMALS; BEHAVIOR; COGNITION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTELLECTUAL DISABILITY; RETT SYNDROME; TRANSLATIONAL MEDICAL RESEARCH; TUBEROUS SCLEROSIS;

EID: 80955148928     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32834c9251     Document Type: Review

References (69)

1. Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999; 23:185-188. (Pubitemid 29455390)
2. Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol 2010; 68:944-950.
3. Kaufmann WE, Tierney E, Rohde CA, et al. Social impairments in Rett syndrome: characteristics and relationship with clinical severity. J Intellect Disabil Res 2011. [Epub ahead of print]
4. Percy AK, Neul JL, Glaze DG, et al. Rett syndrome diagnostic criteria: lessons from the Natural History Study. Ann Neurol 2010; 68:951-955.
5. Armstrong DD. Neuropathology of Rett syndrome. J Child Neurol 2005; 20:747-753. (Pubitemid 41498709)
6. Nan X, Bird A. The biological functions of the methyl-CpG-binding protein MeCP2 and its implication in Rett syndrome. Brain Dev 2001; 23 (Suppl 1):S32-S37.
7. Lasalle JM, Yasui DH. Evolving role of MeCP2 in Rett syndrome and autism. Epigenomics 2009; 1:119-130.
8. Guy J, Cheval H, Selfridge J, et al. The role of MeCP2 in the brain. Annu Rev Cell Dev Biol 2010. [Epub ahead of print]
9. McGraw CM, Samaco RC, Zoghbi HY. Adult neural function requires MeCP2. Science 2011; 333:186.
10. Chahrour M, Jung SY, Shaw C, et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 2008; 320:1224-1229. (Pubitemid 351929512)
11. Skene PJ, Illingworth RS, Webb S, et al. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol Cell 2010; 37:457-468.
12. Zhou Z, Hong EJ, Cohen S, et al. Brain-specific phosphorylation of MeCP2 regulates activity-dependent BDNF transcription, dendritic growth, and spine maturation. Neuron 2006; 52:255-269. (Pubitemid 44548348)
13. Calfa G, Percy AK, Pozzo-Miller L Experimental models of Rett syndrome based on Mecp2 dysfunction. Exp Biol Med (Maywood) 2011; 236:3-19.
14. Monteggia LM, Kavalali ET. Rett syndrome and the impact of MeCP2 associated transcriptional mechanisms on neurotransmission. Biol Psychiatry 2009; 65:204-210.
15. Noutel J, Hong YK, Leu B, et al. Experience-dependent retinogeniculate synapse remodeling is abnormal in MeCP2-deficient mice. Neuron 2011; 70:35-42.
16. Chao HT, Chen H, Samaco RC, et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 2010; 468:263-269.
17. Lioy DT, Garg SK, Monaghan CE, et al. A role for glia in the progression of Rett syndrome. Nature 2011; 475:497-500.
18. Guy J, Gan J, Selfridge J, et al. Reversal of neurological defects in a mouse model of Rett syndrome. Science 2007; 315:1143-1147. (Pubitemid 46328028)
19. Ramocki MB, Tavyev YJ, Peters SU. The MECP2 duplication syndrome. Am J Med Genet A 2010; 152A:1079-1088.
20. Brendel C, Belakhov V, Werner H, et al. Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model. J Mol Med 2011; 89:389-398.
21. Vecsler M, Ben Zeev B, Nudelman I, et al. Ex vivo treatment with a novel synthetic aminoglycoside NB54 in primary fibroblasts from Rett syndrome patients suppresses MECP2 nonsense mutations. PLoS One 2011; 6:e20733.
22. Chang Q, Khare G, Dani V, et al. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron 2006; 49:341-348. (Pubitemid 43152236)
23. Ogier M, Wang H, Hong E, et al. Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome. J Neurosci 2007; 27:10912-10917. (Pubitemid 47535875)
24. Tropea D, Giacometti E, Wilson NR, et al. Partial reversal of Rett syndromelike symptoms in MeCP2 mutant mice. Proc Natl Acad Sci USA 2009; 106:2029-2034.
25. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372:657-668.
26. Jeste SS, Sahin M, Bolton P, et al. Characterization of autism in young children with tuberous sclerosis complex. J Child Neurol 2008; 23:520-525. (Pubitemid 351566864)
27. DiMario FJ Jr. Brain abnormalities in tuberous sclerosis complex. J Child Neurol 2004; 19:650-657. (Pubitemid 39530073)
28. Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 2005; 14 (Spec No. 2):R251-R258. (Pubitemid 41631882)
29. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159-168.
30. Dowling RJ, Topisirovic I, Alain T, et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 2010; 328:1172-1176.
31. Gingras AC, Raught B, Gygi SP, et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 2001; 15:2852-2864. (Pubitemid 33042055)
32. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471-484. (Pubitemid 43199434)
33. Ruvinsky I, Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 2006; 31:342-348. (Pubitemid 43903237)
34. Choi YJ, Di Nardo A, Kramvis I, et al. Tuberous sclerosis complex proteins control axon formation. Genes Dev 2008; 22:2485-2495.
35. Li YH, Werner H, Puschel AW. Rheb and mTOR regulate neuronal polarity through Rap1B. J Biol Chem 2008; 283:33784-33792.
36. Morita T, Sobue K. Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR-p70S6K pathway. J Biol Chem 2009; 284:27734-27745.
37. Nie D, Di Nardo A, Han JM, et al. Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat Neurosci 2010; 13:163-172.
38. Meikle L, Talos DM, Onda H, et al. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci 2007; 27:5546-5558. (Pubitemid 350021088)
39. Kumar V, Zhang MX, Swank MW, et al. Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J Neurosci 2005; 25:11288-11299. (Pubitemid 43083703)
40. Jaworski J, Spangler S, Seeburg DP, et al. Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway. J Neurosci 2005; 25:11300-11312. (Pubitemid 43083704)
41. Tavazoie SF, Alvarez VA, Ridenour DA, et al. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat Neurosci 2005; 8:1727-1734. (Pubitemid 41683201)
42. Meikle L, Pollizzi K, Egnor A, et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 2008; 28:5422-5432.
43. Wang Y, Barbaro MF, Baraban SC. A role for the mTOR pathway in surface expression of AMPA receptors. Neurosci Lett 2006; 401:35-39.
44. Bateup HS, Takasaki KT, Saulnier JL, et al. Loss of Tsc1 in vivo impairs hippocampal mGluR-LTD and increases excitatory synaptic function. J Neurosci 2011; 31:8862-8869.
45. Talos DM, Kwiatkowski DJ, Cordero K, et al. Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers. Ann Neurol 2008; 63:454-465. (Pubitemid 351614711)
46. +/~ mouse model of tuberous sclerosis. Nat Med 2008; 14:843-848.
47. +/~ mice in the absence of cerebral lesions and seizures. Ann Neurol 2007; 62:648-655.
48. Young DM, Schenk AK, Yang SB, et al. Altered ultrasonic vocalizations in a tuberous sclerosis mouse model of autism. Proc Natl Acad Sci USA 2010; 107:11074-11079.
49. Way SW, McKenna J 3rd, Mietzsch U, et al. Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse. Hum Mol Genet 2009; 18:1252-1265.
50. Feliciano DM, Su T, Lopez J, et al. Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice. J Clin Invest 2011; 121:1596-1607.
51. Uhlmann EJ, Wong M, Baldwin RL, et al. Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol 2002; 52:285-296. (Pubitemid 35001494)
52. Zeng LH, Xu L, Gutmann DH, et al. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008; 63:444-453. (Pubitemid 351614710)
53. Wong M, Ess KC, Uhlmann EJ, et al. Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model. Ann Neurol 2003; 54:251-256. (Pubitemid 36909626)
54. Zeng LH, Bero AW, Zhang B, et al. Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of tuberous sclerosis complex. Neurobiol Dis 2010; 37:764-771.
55. Zhou J, Shrikhande G, Xu J, et al. Tsc1 mutant neural stem/progenitor cells exhibit migration deficits and give rise to subependymal lesions in the lateral ventricle. Genes Dev 2011; 25:1595-1600.
56. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363:1801-1811.
57. Tyler WA, Gangoli N, Gokina P, et al. Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation. J Neurosci 2009; 29:6367-6378.
58. Narayanan SP, Flores AI, Wang F, et al. Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J Neurosci 2009; 29:6860-6870.
59. Harrington EP, Zhao C, Fancy SP, et al. Oligodendrocyte PTEN is required for myelin and axonal integrity, not remyelination. Ann Neurol 2010; 68:703-716.
60. Ridler K, Bullmore ET, De Vries PJ, et al. Widespread anatomical abnormalities of grey and white matter structure in tuberous sclerosis. Psychol Med 2001; 31:1437-1446. (Pubitemid 33040367)
61. Zikou A, Ioannidou MC, Tzoufi M, et al. Magnetization transfer ratio measurements of the brain in children with tuberous sclerosis complex. Pediatr Radiol 2005; 35:1071-1074. (Pubitemid 41554575)
62. Makki MI, Chugani DC, Janisse J, et al. Characteristics of abnormal diffusivity in normal-appearing white matter investigated with diffusion tensor MR imaging in tuberous sclerosis complex. AJNR Am J Neuroradiol 2007; 28:1662-1667. (Pubitemid 47598136)
63. Yu C, Lin F, Zhao L, et al. Occult white matter damage contributes to intellectual disability in tuberous sclerosis complex. Intelligence 2009; 37:174-180.
64. Piao C, Yu A, Li K, et al. Cerebral diffusion tensor imaging in tuberous sclerosis. Eur J Radiol 2009; 71:249-252.
65. Krishnan ML, Commowick O, Jeste SS, et al. Diffusion features of white matter in tuberous sclerosis with tractography. Pediatr Neurol 2010; 42:101-106.
66. Urdinguio RG, Fernandez AF, Lopez-Nieva P, et al. Disrupted microRNA expression caused by Mecp2 loss in a mouse model of Rett syndrome. Epigenetics 2010; 5:656-663.
67. Wada R, Akiyama Y, Hashimoto Y, et al. miR-212 is downregulated and suppresses methyl-CpG-binding protein MeCP2 in human gastric cancer. Int J Cancer 2010; 127:1106-1114.
68. Marchetto MC, Carromeu C, Acab A, et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010; 143:527-539.
69. Kim KY, Hysolli E, Park IH. Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome. Proc Natl Acad Sci USA 2011; 108:14169-14174.